Bray Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Bray Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$1.83M	Buy	4,554 +624	+16%	+$289K	0.5%	56
2024 Q3	$1.83M	Hold	3,930	–	–	0.45%	59
2024 Q2	$1.84M	Hold	3,930	–	–	0.46%	57
2024 Q1	$1.64M	Hold	3,930	–	–	0.42%	61
2023 Q4	$1.6M	Hold	3,930	–	–	0.44%	58
2023 Q3	$1.37M	Hold	3,930	–	–	0.42%	58
2023 Q2	$1.38M	Hold	3,930	–	–	0.41%	61
2023 Q1	$1.24M	Hold	3,930	–	–	0.36%	69
2022 Q4	$1.13M	Hold	3,930	–	–	0.35%	69
2022 Q3	$1.14M	Hold	3,930	–	–	0.36%	68
2022 Q2	$1.11M	Hold	3,930	–	–	0.33%	74
2022 Q1	$1.03M	Hold	3,930	–	–	0.26%	84
2021 Q4	$863K	Hold	3,930	–	–	0.21%	94
2021 Q3	$713K	Buy	3,930 +190	+5%	+$37.1K	0.18%	99
2021 Q2	$754K	Buy	3,740 +350	+10%	+$73.2K	0.19%	94
2021 Q1	$728K	Hold	3,390	–	–	0.2%	92
2020 Q4	$801K	Buy	3,390 +865	+34%	+$198K	0.23%	87
2020 Q3	$687K	Buy	+2,525	New	+$697K	0.24%	84

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Bray Capital Advisors's VRTX Position: Q4 2024 in Review

Bray Capital Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 16% in Q4 2024, buying an estimated $289K and bringing the position to 4,554 shares worth $1.83M. The position accounts for 0.5% of the portfolio, ranked #56.

Bray Capital Advisors first reported a position in VRTX in Q3 2020 and has held it in 18 quarters since. The position peaked at $1.84M in Q2 2024. 1,557 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

Bray Capital Advisors held 4,554 shares of Vertex Pharmaceuticals worth $1.83M as of Q4 2024.
Bray Capital Advisors bought 624 Vertex Pharmaceuticals shares in Q4 2024, an estimated $289K.
Vertex Pharmaceuticals made up 0.5% of Bray Capital Advisors's portfolio in Q4 2024, its #56 holding.
Bray Capital Advisors first reported a position in Vertex Pharmaceuticals in Q3 2020 and has held it in 18 quarters since.
Bray Capital Advisors's Vertex Pharmaceuticals position peaked at $1.84M in Q2 2024.
1,557 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on Bray Capital Advisors's 13F filing for Q4 2024, filed 3 Feb 2025.